Urine 5MedC, a Marker of DNA Methylation, in the Progression of Chronic Kidney Disease

Table 2

A multiple logistic regression analysis to determine low eGFR (later CKD stages, <30 mL/min/1.73 m²) in different models.

	Odds ratio	95% CI	value
Model 1
u5MedC ≥ median (μmol/gCr)	2.30	1.29 - 4.21	0.005
Model 2
u5MedC ≥ median (μmol/gCr)	2.16	1.18 – 4.04	0.012
UAE ≥ 300 (mg/gCr)	4.31	2.36 – 8.08	<0.0001
Model 3
u5MedC ≥ median (μmol/gCr)	2.36	1.24 - 4.60	0.008
UAE ≥ 300 (mg/gCr)	1.39	0.67 - 2.90	0.381
uα1MG ≥ median (mg/gCr)	13.56	5.32 – 40.1	<0.0001

Adjusted for age and gender. The median values of u5MedC and uα1MG are 65.9 (μmol/gCr) and 5.7 (mg/gCr), respectively. CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; UAE, urinary albumin excretion; uα1-MG, urinary α1-microglobulin; u5MedC, urinary 5-methyl-2’-deoxycytidine; CI, confidence interval.